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1. Introduction 
After the hypothesis of ‘immune surveillance’ in tumor proposed in 1970, several 
investigations showed the evidences of its existence where immune system is able to 
recognize the defects due to tumor onset (MacFarlan Burnet, 1970). But how far this 
surveillance is effective in the compartmentalized brain in case of glioma still remains a big 
uncertainty. Glioma is one of the deadliest types of cancer for its rapid growth, invasiveness 
and short life expectancy of the victim. So, figuring out of the extent of host immune 
efficiency in glioma is crucial. As glioma is able to create a hostile environment for the 
immune cells by releasing different soluble factors, expressing death receptors and by 
receptor camouflaging etc, the working situation for the host immunity becomes more 
difficult. Therefore, proper assessment of the role of brain immune connection in glioma is 
crucial to explore the probable level of support that can be extended by the immune defense 
mechanism against glioma. This immune resistance is also vital to support the present 
therapeutic modalities including adjuvants used for treating glioma. 
2. Death of ‘Privilege’ myth: Immunocytes do not spare brain from their 
vigilance 
2.1 ‘Immune privilege’ of brain: A notion that prevailed more than 5 decades 
At the beginning of 20th Century, brain was thought to be a separate organ mostly 
abandoned by the immune system. The initial evidences of immune compromise of the 
brain compartment were observed from 1920s with the tumor tissue transplantation studies. 
Rat sarcoma, when transplanted in mouse brain parenchyma, was found to grow better in 
comparison to its subcutaneous and intramuscular (systemic) transplantations (Shirai, 1921). 
On contrary, when portions of recipient spleen were co-transferred with tumor in brain 
parenchyma, inhibition in tumor growth occurred (Murphy and Sturm, 1923). Thus a weak 
or less efficient immune intervention in brain was conceptualized and the term ‘immune 
privilege’ was proposed by Billingham and Boswell (Billingham & Boswell, 1953).  
With this, another set of observations in late 19th century and afterwards developed a 
concept of existence of a barrier between blood and CNS tissue. Basically, Paul Ehrlich’s 
observation with the intravenous administration of vital dye in experimental animals 
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showed infiltration of the dye in other organs except brain. That led him to propose a barrier 
between brain and blood stream (Ehrlich, 1885 & 1904). Goldmann’s study showed that 
tracers injected in blood do not enter into the parenchyma proper in brain, but accumulated 
in the choroid plexus, perivascular space or lymphatic clefts (Obersteiner, 1870; Goldmann, 
1913). The ‘no entry’ status of blood immunocytes was further fueled with the xeno- and 
allogenic tissue transplantation studies (Medawar, 1948; Barker & Billingham, 1977). In the 
following decades ultrastructural studies of the blood capillaries in brain showed the 
distinct cellular organization present in the interphase of blood and brain that prevent the 
flow of blood immunocytes and large molecular weight solvents into brain (Reese & 
Karnovsky, 1967; Engelhardt & Wolburg, 2002). Thus blood-brain-barrier (BBB) 
encapsulates the brain and seems to maintain the ‘immune privilege’ status. Till 1980s no 
direct lymphatic drainage from nervous system was detected. Negligible expression of 
MHC and undetected dendritic cells (DC) in brain indicated the inefficiency of antigen 
presentation in the organ (Sedgwick, 1995; Perry, 1998). 
2.2 Detection of secret routes connecting brain with systemic circulation 
But in last two decades a paradigm shift has occurred in this ‘immune privilege’ rank of 
brain. Basically, three obstacles that maintain the privilege are – i) lack of drainage of CNS 
antigens at least to cervical lymph node, ii) hindrance to easy access of T cells in the CNS 
parenchyma and iii) T cells require antigen presentation in the reaction site by the APCs 
which were thought to be scarce in brain. Initial experiments suggested that CNS antigens 
can drip outside passively by a different route along the olfactory nerves on to the 
cribriform plate which is connected to the lymphatics of nasal submucosa and finally to the 
cervical lymph node (Cserr & Knopf, 1992; Sedgwick, 1995). Tracer studies indicated CSF 
drainage to cervical lymph node (Boulton et al, 1999). CSF circulates from ventricles through 
subarachnoid spaces (a space between arachnoid and pial membrane filled with CSF and 
surround the brain and spinal cord) and it has access to Virchow-Robin space that 
surrounds blood vessels when they enter brain parenchyma [Figure – 1]. Ependymal lining 
of the ventricles lack ‘tight junctions’ and in other specialized perivascular spaces including 
Virchow-Robin’s that porosity is also present, which help in clearance of interstitial fluid 
from brain parenchyma (Ransohoff et al, 2003; Piccio et al, 2002). So the protein antigens 
have the probable, though slightly difficult than other organs, access to the lymphoid tissue 
through CSF. This generates opportunity for the passage of immunocytes.  
The afferent arm of CNS immune response is initiated with the antigen leakage from brain 
parenchyma to CSF; whereas the efferent arm is largely progressed with the migration of 
leukocytes to CNS into different routes. Ransohoff and colleagues identified three distinct 
routes which are – i) cells from blood extravasate through choroid plexus to the CSF, ii) 
leukocytes flowing through internal carotid artery cross the post capillary venules in the 
subarachnoid space and Virchow-Robin perivascular space and iii) finally leukocytes may 
cross the BBB deep into the brain to enter directly into the brain parenchyma (Ransohoff et 
al, 2003). Precisely speaking, BBB is a metaphor that describes the property of brain 
vasculatures restricting the entry of large molecules and cells (Bechmann et al, 2007). The 
perivascular spaces exist in the pre- and post-capillary segments in brain where a 
heterogeneous assembly of lymphocytic and monocytic cells are observed, more during 
inflammation. Both in the perivascular spaces and after entering into parenchyma they 
encounter antigen presenting cells (APCs) to continue the immune response in brain. 
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Fig. 1. This figure represents routes of CNS antigen escape and immune cell connection from 
brain to peripheral circulation. T cells initially are primed by the CNS antigen leaked from 
brain to the cervical lymph node or olfactory bulb or nasal mucosa, become activated and 
reach to the blood vessel, subarachnoid area, Virchow-Robin space or perivascular space 
and CSF in brain. There also a repriming of the glioma antigen specific lymphocytes occurs 
by the APC circulating or residing at those spaces. Choroid plexus is also a very important 
route of this CNS antigen escape and site of antigen presentation to lymphocytes by the 
local APCs. These specific glioma antigen primed activated lymphocytes enter into the brain 
parenchyma and invade towards glioma. [The box has been elaborated in Figure – 4] 
2.3 Lymphocytes assess CNS antigen and enter into neuropil 
2.3.1 T cells can pass into neuropil and interact with brain APCs 
Early experiments showed that though graft rejection is comparatively slow in brain, once 
the graft is familiar to the immune system outside brain, the rejection occurs rapidly (Mason 
et al, 1986; Sedgwick, 1995). Simultaneously, Wekerle and colleagues demonstrated that 
activated or antigen primed T cell from the periphery can cross the BBB nonspecifically 
(Wekerle et al, 1986). Following experiments supported the fact when it was found that 
CD4+ T cell blasts of any specificity injected intravenous to experimental animals can pass 
into CNS tissue, although myelin antigen specific T cells are found to remain longer (Hickey 
et al, 1991). This delay of the myelin antigen specific T cells suggests some mechanism that 
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holds them to process and react in brain parenchyma. The answer is the cross-talk between 
them and microglia (or brain APC). Microglia is found ex-vivo to induce IFN-Ǆ and TNF 
production from CD4 T cells as their effector activation, but do not support proliferation by 
IL-2 and induce apoptosis. Interestingly, perivascular macrophages show activation with IL-
2 mediated proliferation and survival of CD4+ T cells (Ford et al, 1996).  
 
 
Fig. 2. This section of brain parenchyma shows a blood capillary containing leukocytes. 
Many of them are at the margin of the capillary, tethering the endothelium and 
extravaseting at the perivascular spaces. Perivascular microglia/macrophage are visible. 
Few infiltrated leukocytes are found scattered in brain parenchyma. At least one rod shaped 
ramified microglia is detectable in the parenchyma. A simple H/E staining section of brain 
furnishes these visual evidences of neuro-immune connection. (Magnification 1000X, oil 
immersion in Olympus CH20i Microscope and photographed by Olympus DSC) 
The reverse is also visible in the GvHD affected CNS model where CD4+ǂǃTCR+CD2+T cells 
infiltrat and scatter deep into neuropil or brain parenchyma. The microglial cells show 
activation with many fold increase in their CD11b/c, CD45 and MHC class II expression and 
cluster with intimate association with these T cells in situ that lead to microglial activation, 
proliferation and expansion (Sedgwick et al, 1998). Thus both microglia and infiltrated 
lymphocytes influence each other for their maturation and effector function in brain. 
With the citations of entry of lymphocytes in brain, the role of CNS APCs started to come 
into surface. They are subdivided as microglia and perivascular macrophages based on their 
position, morphology, immunophenotype and functional priority (Sedgwick et al, 1991; 
Bechmann et al, 2001). Therefore entry of lymphocytes into neuropil through pre- and post-
capillary vessels needs a two step process. Crossing the vessel endothelium, muscle layers 
and basement membranes lymphocytes and blood borne monocytes reside at the 
perivascular space encapsulated with glial limitans and pericytes. Next step is more 
restricted where the leukocytes cross the layer of glial limitans and step in to neuropil 
(Bechmann et al, 2007). To proceed for this step, brain APC associated with this limiting 
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layer is crucial (Tran et al, 1998; Greter et al, 2005) [Figure – 2]. Then the infiltrated 
lymphocytes may come across the APC present in the brain parenchyma or at the site of 
pathogenesis. The T cell-microglia interactions in CNS autoimmune encephalomyelitis 
(EAE) or brain tumor; T cell secretion of Th1 cytokines to mature microglia as functional 
APC and resulting restimulation of leukocytes by them; counter regulation of this 
inflammation by Th2 induction by microglia etc had been detailed mostly on the functional 
studies committed so far (Aloisi et al, 2000; Ghosh & Chaudhuri, 2010). 
2.3.2 Cell tracking experiments visualize leukocyte access in brain 
But a new generation of cell tracking experiments and lebelling methods now provide us 
more direct evidences of the events occurring beneath the skull. GFP-labelled unspecifically 
activated CD4 T lymphocytes when injected into cortex and ventricle of mice brain, there 
path through the cross-section of entire head-neck region was monitored. Irrespective of the 
sites, it was visualized that they pass through the cribroid plate, reach to nasal mucosa and 
accumulate in the cervical lymph node (Goldmann et al, 2006). Shifting the focus on CD8+ T 
cells, it was recently found that selective traffic of antigen specific CD8 T cells occurs in 
brain. Using immunofluroscence and confocal micrographs it was found that the process is 
dependent on luminal expression of MHC class I by cerebral endothelium in response to 
intracerebral antigen injection. Significantly, the process is quite independent of 
perivascular macrophages and different from CD4+ T cell entry (Galea et al, 2007). After 
visualizing the entry and exit of T cells from brain their activities in the brain needs a close 
watching. 
3. But glioma makes the immune system puzzled 
Despite the efforts of host immune system, which Burnet and Thomas described as ‘immune 
surveillance’, malignant glioma can evade and overcome this defense to grow. There are 
several generalized strategies for the tumor cells to bypass the immune resistance. They can 
be simply categorized as follows –  
a. Making the immune system ignorant about the tumor growth by lacking the tumor 
antigens in lymphoid organs, growing in immune privileged position, creating physical 
barriers by stoma, lacking adhesion molecules for cellular interactions etc. 
b. Actively impairing and suppressing the immune system by down-regulating the 
expression of MHC genes or imposing defects in antigen processing, secreting 
suppressive cytokines like TGF-ǃ, IL-10 etc and other factors like prostaglandins.  
c. Inducing tolerance to immune system by minimizing costimulation that results into 
anergy and central tolerance to the tumor antigen as many of them produce self-
antigens or mimic them. Regulatory T cell mediated inhibition of DC maturation and T 
cell activation in the tumor environment plays a crucial role for dampening the immune 
resistance. 
d. Counter attacking the immune system by expressing different death receptor ligands 
like CD95L, decoy receptors, TRAIL family etc and expressing anti-apoptotic molecules 
for themselves.  
Glioma adapt most of these mechanisms successfully with their additional advantage to 
grow in a position which has been visited or monitored by the peripheral immune cells less 
frequently and less aggressively. 
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3.1 Glioma drastically reduces immune efficiency 
Different studies on a number of patients harboring glioma revealed that they suffered from 
impaired cell mediated immunity (Elliott et al, 1984). In vitro studies showed that peripheral 
blood lymphocytes (PBL) obtained from patients with gliomas proliferated poorly in 
response to mitogen and/or antigen stimulation in vitro and unresponsiveness to T-cell 
mitogens concanavalin A (ConA), phytohemagglutinin (PHA) and anti-CD3 mAb etc 
(McVicar et al, 1992). A number of potential mechanisms explaining the observed immune-
suppression including qualitative or quantitative alterations in cell surface marker 
expression on T-cells, elevated suppressor cell activity or T-cell lymphopenia were explored. 
T-cells obtained from glioma patients have intrinsic defects, which synthesize and secrete 
less than normal levels of interleuken-2 (IL-2) required for T-cell proliferation. IL-2 mRNA 
synthesis is impaired with less production of IL-2 receptor (IL-2R), and they also are unable 
to enter G1 phase of cell cycle (Elliott et al, 1990). Additionally, the numbers of CD4+ T-cells 
obtained from patients are reduced to a great extent than CD8+ T-cells, which predominately 
infiltrate glioma, but are deprived from CD4+ help. Based on their inability to produce and 
respond to IL-2 and lack of CD4+ help, T-cells obtained from glioma patients appear to be 
anergic (Elliott et al, 1990; Giometto et al, 1996).  
Wide level of T-cell signaling defects are observed in glioma patient derived T-cells. T-cells 
from glioma patients show reduced tyrosine phosphorylation compared to normal T cells, 
which is mostly reduced in PLCǄ1. Additionally, both PLCǄ1 and p56lck protein levels are 
found reduced dramatically and thus it causes the overall impairment of TCR/CD3-
mediated signaling. Reduced p56lck and associated signals also resists the cells to make 
sufficient contact with APCs, reduced their appropriate stimuli and movements (Marford et 
al, 1997, Dix et al, 1999). Severe T-cells lymphopenia i.e. rapid depletion of the cells is an 
important feature of glioma patients. As CD4+ T-cells are reduced in number and less 
responsive to mitogens and antigens, IL-2 and IFNǄ production decreases further. Because 
both these cytokines are important for generation of LAK cells and CTL activity, they are 
responsible for impaired generation of antigen-stimulated, MHC-unrestricted cytotoxicity 
observed in glioma patients (Urbani et al, 1996; Dix et al, 1999). Even glioma condition 
facilitates to increase Th2 type IL-10 production and inhibit Th1 type IL-12 and TIL secrete 
predominantly Th2 type cytokines underscoring the Th1 effect. Glioma has been shown to 
synthesize and secrete multiple factors including TGFǃ, PGE2, IL-10 and gangliosides (Zou 
et al, 1999, Huettner et al, 1997). Gliomas synthesize and secrete TGFǃ1, 2, and 3 which down-
regulate monocyte surface marker expression, cytokine secretion, cytotoxicity and T-cell 
responsiveness. Gangliosides (GANGs) are components of human plasma with GM3 and GD3 
being major constituents, and can bind to both plasma proteins and lipoproteins. The 
highest concentrations of GANGs are found in brain and mainly include GM1, GD1a, GD1b and 
GI1b. These are highly immunosuppressive by inhibiting T-cell proliferation, CD4 
expression, generation of CTL and NK cell activity. In addition, GANGs may also suppress 
Ca2+ flux in T-cells (Ladisch et al, 1992; Zou et al, 1999; Dix et al, 1999). 
3.2 The mechanism behind glioma immune evasion 
Like any other tumors immune selective pressure on the glioma cells is also working to 
eradicate abnormal cells. Though the initial intensity is less and additional time is required 
to recognize and react, the precision is much higher against the neoplastic cells in brain 
(which will be discussed in the following sections). The genetic instability of glioma and 
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their repeated exposure to immune selection act as the key to develop glioma cell variants 
with enhanced capacity to evade immune defense. 
Glioma cells are capable to secret copious factors that influence the immune system 
negatively. Cyclooxygenase enzyme COX-2 derived prostaglandin E2 (PGE2) bind with its 
receptor EPI-4 on glioma cells and encourage them to invade by increasing motility. PGE2 
downregulate Th1 cytokines like IL-2, IFNǄ and TNFǂ, and upregulate Th2 cytokines like 
IL-4, IL-10 and IL-6 (Wang & Dubois, 2006). Glioma cells secrete IL-10 which inhibit IL-2 
induced T cell proliferation, DC and macrophage activation (Grutz, 2005). IL-10 is expressed 
by Treg cells present in glioma vicinity (Sakaguchi, 2005). TGFǃ with its three isoform 
(TGFǃ1,2,3) is involved in regulating inflammation, angiogenesis and proliferation 
(Govinden and Bhoola, 2003). TGFǃ is the dominant isoform expressed by glioblastoma. 
They inhibit maturation of professional APCs, obstruct the synthesis of cytotoxic molecules 
including perforin, granzymes, FasL in activated CTL (Thomas and Massague, 2005). This 
cytokine may also efficiently recruit T reg cells in glioma. Glioma shows a considerable level 
of resistance against Fas induced apoptosis. Decoy receptor 3 (DcR3) is expressed in brain 
tumor and prevents Fas mediated apoptosis as well as decreases infiltration of CD4 and 
CD8 T cells (Roth et al, 2001). Apoptosis inhibitory proteins (IAPs) are active in glioma 
which inhibit caspase activity (Gomez & Kruse, 2006). Some of the glioma cells express FasL 
to counteract with the immunocytes (Husain et al, 1998). 
As cell to cell contact plays an important role to deliver the immune assault, glioma cells 
take the strategy to minimize or impair these adhesions. Cell adhesion interaction between 
glioma and immune cells was found to be prevented by a thick glycosaminoglycan coating 
and protect the neoplastic cells from CTL action (Dick et al, 1983). In glioma condition, 
ICAM-1/LFA-1 interaction is interrupted which inhibit target cell lysis by tumor specific T 
and NK cells (Schiltz et al, 2002; Fiore et al, 2002). The aberrant HLA class I expression in 
glioma helps them to evade T cell detection of transformed cells and subsequent cytotoxicity 
(Rosenberg et al, 2003). In glioma, B7-H1 (B7-homologue 1, a costimulatory molecule) 
inhibits allogenic T cell activation and associated cytokine secretion (Wilmotte et al, 2005).  
Some other factors like Indoleamine 2,3-dioxygenase (IDO) expression in glioma cells cause 
T cells to starve for tryptophan, cell cycle arrest and tolerance (Uyttenhove et al, 2003). 
Interestingly, IFNǄ stimulate IDO production in glioma, create a local tryptophan shortage 
and T cell tolerance (Shirey et al, 2006). The activation of STAT-3 is another trick for glioma. 
STAT-3 regulates the anti-apoptotic proteins like Bcl-2, Bcl-XL, Mcl-1, cFLIP, surviving etc in 
glioma (Rahaman et al, 2005; Akasaki et al, 2006). Glioma uses various factors including 
chemokines and matrix degrading enzymes secreted from the brain macrophage/microglia 
population for their migration and spread in brain (these will be discussed later). 
4. Undaunted immune effort continues to resist transformed cells 
4.1 T cells mature to effector state after local interaction with APCs in CNS, even in 
brain tumor 
The experimental evidences furnished by Ford and his colleagues in 1996 revealed that the 
resident antigen presenting cell of brain i.e., microglia, interacts with the T cells to induce 
final effector function (Ford et al, 1996). Years’ later studies with GFP-labeled 
encephalitogenic T cells specific for MBP (TMBP-GFP cells) showed that, with the onset of the 
disease, huge number of CD4+ effector cells infiltrate in CNS with upregulated chemokine 
receptors. But these infiltrated TMBP-GFP cells when recovered after 24 hrs from brain 
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parenchyma or neuropil they showed fresh sign of reactivation with upregulation of OX-40 
and IL-2R, and upregulated expression of IFNǄ, TNFǂ, TGFǃ, IL-2, IL-10, CD3 mRNA 
expression (Flugel et al, 2001). These observations suggested the importance of brain APC at 
the site of proper functioning of the recruited cells.  
 
 
Fig. 3. The section shows that infiltrated lymphocytes in brain parenchyma interact with 
transformed oligodendroglial cells in a murine oligodendroglioma model and offer them the 
‘kiss of death’. One oligodendroglioma cell nucleus is protruded out of the cytoplasm and 
for the other cell, the lymphocyte is overlapping with it. One oligodendroglioma cell, one 
astrocyte and a free lymphocyte is visible in the field. (Magnification 1000X, oil immersion 
in Olympus CH20i Microscope and photographed by Olympus DSC) 
The function of APC is now becoming more substantial in CNS as some new experimental 
evidences indicate that they are important to reshape and retain Ag-specific CTLs in the site 
of neuropathogenesis. In a series of experiments Walker and team addressed the issue with 
precision. Whether CNS retention of tumor specific MHC class I restricted CD8+ T cells also 
require recognition of local APC cross-presenting tumor Ag was the problem under 
scrutiny. They used murine glioma transfected with cDNA encoding HLA-CW3 implanted 
in mice model. The observation was a massive expansion of H2Kd/CW3170-179-specific CTL 
using BV10TCR after immunization with CW3. In that animal model the endogenous 
presentation was tactically avoided and due to the absence of MHC class II on MT-CW3 
transfect, the CD4 arm is also avoided. Therefore any expansion of H2Kd restricted CW3-
specific CTL suggests the involvement of hosts APC at the tumor site. Detection of the 
localization of specific CTL, their cytotoxic efficacy and retention of effector functions in an 
antigen dependent manner speaks the importance of local APC within CNS (Calzascia et al, 
2003). They are activated macrophage/microglia and cells with DC phenotype found 
infiltrated heavily in tumor. In subsequent studies they also provide support for the fact that 
T cell homing at the specific CNS tumor site is defined by the cross-presentating APCs there 
and not predetermined in the lymph nodes where initial priming occurs (Calzascia et al, 
2005). In extended studies it was further found that Ag-experienced CD8+ T cells further 
differentiate at the intracerebral tumor site with enhanced IFNǄ and Granzyme-B expression 
and induction of ǂEǃ7 integrin that facilitate their retention in brain (Masson et al, 2007). 
Thus cytotoxic activity of lymphocytes on glioma is not rare [Figure – 3]. 
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4.2 Microglia, the local/resident APCs of brain accumulate in glioma 
Microglia is designated as local or resident antigen presenting cell throughout the brain 
parenchyma or neuropil and its margin. Most emphatic efforts of microglial research in the 
last two decades were invested to explore its functional relevance in the brain tissue. The 
striking feature of microglia is its versatile ability to respond according to the CNS 
microenvironment. Functionally speaking, microglia is a hybrid between white blood cells 
and glial cells, which is intended to protect and support the neuronal environment in brain. 
Microglia can respond against an extensive list of biochemical factors ranging as diverse as 
glycoconjugates, neurotransmitters or cytokines/chemokines (Nakamura, 2002).  
Nearly two decade of studies demonstrated the causative effects of chemokines in glioma 
microenvironment for macrophage/microglia infiltration. The C-C family chemokines, viz, 
monocyte chemotactic protein 1 (MCP-1) was first purified from glioma and Leung et al, 
1997 found that with increased MCP-1 the macrophage/microglia infiltrates in glioma. 
Astrocytoma cells were found capable of producing MCP-1, and complementary receptor 
CCR2 was present and expressed on activated microglia (Leung et al, 1997). In 2003, 
evidence showed that, MCP-1 promoted the microglial migration in glioma and microglia 
infested glioma grew rapidly (Platten et al, 2003). The involvement of PI-3K/Akt pathway 
was assumed in the secretion of microglia derived factors that mediate glioma invasiveness 
(Joy et al, 2003; Pu et al, 2004). CSF-1 (colony stimulating factor 1), which acted as 
chemotactic and mitogenic factors for myeloid lineage cells, and its receptor, were long been 
detected in glioma, whereas microglia also possessed the option of secreting and receiving 
the factor from self and neighboring cells. Eventually from glioma G-CSF/GM-CSF 
(granulocytes and granulocytes macrophage colony stimulating factor) were secreted and 
influenced the differentiation and maturation process of microglia like other myeloid 
lineage cells. Badie et al, 1999, in vitro demonstrated the specific microglia attracting capacity 
of glioma by the hepatocyte growth factor/scatter factor (HGF/SF). HGF/SF signals the 
spectrum of mesenchymal cells for mitogenic stimulation, invasion and extravasation. 
Microglia possesses its receptor Met and can produce HGF/SF, whereas the glioma cells are 
capable of doing the same (Badie & Schartner, 2001). Thus, the balancing ratios of the factors 
in glioma microenvironment act as the determinant in the migration process of the cells. 
In 2002, the 15.3 KDa heparin-binding peptide Pleiotrophin (PTN) was found to appear in 
adult human glioma, normally a mitogenic/angiogenic factor in embryonic stage. Uniquely, 
PTN did not help to proliferate the glioma cells by its own, rather influenced microglial 
accumulation by acting as strong chemotactic and mitogenic agent. Its action thus passively 
helped glioma growth by targeting endothelial and microglial cells (Mentlein & Held-
Feindt, 2002). The question arose that what would be the interest of glioma to include 
microglia in its vicinity? In fact, the role of infiltrating macrophage/microglia in the process 
of angiogenesis in glioma was hinted previously when macrophage associated heme-
oxygenase-1 (HO-1) enzyme was found to be correlated with the vascular density of human 
glioma (Nishie et al 1999). Another enzyme cyclooxygenase (COX)-2 was found to be 
produced in higher amount in microglia isolated from intracranial glioma which increased 
the prostaglandin E2 (PGE2) production. The study suggested that glioma infiltrating 
microglia contributed in developing fatal cerebral edema in glioma through COX-2 
dependent pathway. It was reported that PGE2 increased the permeability of vascular 
endothelium by cytoskeletal rearrangement where TNFǂ acted as positive inducer. In that 
case, microglia was the source of both COX-2 and TNFǂ probably playing a role in its own 
migration, leukocyte trafficking and in parallel, glioma invasiveness (Badie et al, 2003).  
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Contrary to the reports and assumptions, others demonstrated that TNF dependent action 
enhanced the macrophage/microglia recruitment in glioma where they form small cavities 
named microcysts and reduces the glioma growth (Villeneuve et al, 2005). A report stated 
that, the infiltrated macrophages (CD11b+CCR3-CD45high) caused TNF induced apoptosis in 
GL261 glioma cells where related microglial cells (CD11b+CCR3+CD45+) were negligible 
(Nakagawa et al, 2007). Actually the thin line of demarcation of cellular identity between 
macrophage and microglia could not exclude any of them from the function of TNF 
dependent glioma elimination. Opposing the recent believe of pro-tumoregenic role of 
macrophage population in different tumors, the reports raised question against application 
of anti-inflammatory drugs to suppress microglial action in glioma. To reestablish its role 
against glioma, the mechanism of their phagocytic recognition, killing machinery, and 
antigen presentation to CTL etc must have to be introspected more specifically. 
4.3 Microglia protects host brain as well as support glioma: A bi-edged sword 
Further findings showed that microglia helped glioma to invade by releasing matrix 
degrading enzymes. Even it was recently found that in rare Neurofibromatosis 1 (NF1), the 
heterozygote microglia had the role to promote glioma growth (Daginakatte & Gutmann, 
2007). In 2005, it was found that metalloprotease-2 (MMP-2) activity was increased in 
microglia by the soluble factors released from glioma cells (Markovic et al, 2005). Thus 
glioma in turn influenced microglia to invade and migrate, which was utilized by neoplastic 
cells itself to spread and grow. Previously, a separate study hinted the process when the 
motility of GL261 mouse glioma cells was assessed in presence of microglia. Even the 
microglia stimulated with GM-CSF or LPS enhanced this migration (Bettinger et al, 2002). 
Adenosine mediated anti-inflammatory effects on macrophage cell lines by modulating the 
cytokine balance was observed. Additionally, macrophage and microglia both the cells were 
found to present adenosine receptors. In 2006, Synowtz and his team found the effect of 
nucleoside Adenosine on microglial cell and glioma. Deficiency of A1 adenosine receptor 
(A1AR) on microglia helped to grow the GL261 glioblastoma cells and increased number of 
A1AR expressing microglia in the site inhibited this growth. The mentioned study also 
hinted that adenosine signaling through the receptor depleted glioma influenced microglial 
MMP-2 release, which in turn restricted glioma growth and invasion (Synowitz et al 2006). 
Again, Kettenmann and colleagues observed that Microglia express membrane type 1 
metalloprotease (MT1-MMP) in glioma condition, which helps to activate glioma released 
pro-MMP2 and thus promotes the spread of glioma in brain parenchyma (Markovic et al, 
2009). Their most recent finding is that the antibiotic minocycline attenuates microglial MT1-
MMP expression in glioma and as a result neoplastic cell expansion is reduced in glioma 
(Markovic et al, 2011). 
Plasticity, its migration to the site of injury or inflammation, response and then departure 
from the site required a plausible explanation mostly for its movement. Microglia was found 
to express ǂ6ǃ1 integrin, which was the receptor for laminin expressed on the extracellular 
matrix constituent projections of astrocytes. This particular adhesion was for migration and 
under strict control of cytokine milieu (Milner & Campbell, 2002). It was found recently that 
another integrin ǂ5ǃ1 expressed both on glioma and microglial cells were capable of 
inhibiting glioma growth when attenuated. Remarkably it was found that, the attenuation 
process and resulting depletion of glioma required the presence of microglial cells (Färber et 
al, 2008). It might be probable that microglia secreting products had control over this 
integrin-laminin adhesion and migration of cell itself and invasive migration of glioma cells. 
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Regarding the cytokine microenvironment, the role of TGF-ǃ was hinted in migration 
(Milner & Campbell, 2002). The specific importance of the cytokine was demonstrated by 
RNAi mediated gene silencing of TGF-ǃ in promoting growth and invasiveness of glioma by 
integrin family adhesion molecule (Wesolowska et al, 2008). Recently it was found that 
cyclosporin A (CsA), an inhibitor of calcineurin and immunosuppressive in effect, could 
inhibit microglia mediated glioma invasion and cause to change morphological structure of 
microglia via MAPK signaling (Silwa et al, 2007). 
In the present context, most of the studies demonstrated pro-tumerogenic action of microglia 
in glioma, which was facilitated by the secretary products, signaling molecules including 
cytokines, chemokines and receptors etc. In parallel, glioma cells favor microglial migration 
and encroachment in its vicinity. Though primarily macrophages/microglia are the cells to 
defend host tissue from faulty or malfunctioning cells or pathogens, their pro-glioma role 
leads to confusion. Remarkably, several findings also came with hopeful antagonistic results as 
already mentioned, where the roles of TNFǂ, TGFǃ, A1AR dependent MMP-2 inhibition etc 
were focused (Villeneuve et al, 2005; Nakagawa et al, 2007; Synowitz et al 2006; Wesolowska et 
al, 2008). In 2007, Galarneau and team demonstrated that macrophage/microglia depletion 
helped in glioma growth (Galarneau et al, 2007). The study hinted for a separate anti-tumor 
potential of the cells. These contradicting results present microglia with a double agent stature.   
4.4 Glioma antigen presentation by microglia 
To determine the antigen presenting role of microglia their MHC class II expression along 
with the co-stimulatory molecule like B7.1 (CD80) and B7.2 (CD86) had been evaluated. 
Badie and his team found the lower level of expression of these essential surface molecule 
for APC function in microglia freshly isolated from glioma invasive cells and that suggested 
suppressive effect on glioma microenvironment in vivo (Badie & Schartner, 2001). In a 
comparative study of different rodent glioma model viz., C6, 9L and RG2, the expression 
profile was found to vary significantly depending on the immunogenicity of the model. The 
costimulatory B7 molecule expression could be favored when microglia were rejuvenated by 
cytokines GM-CSF and IFN-Ǆ in vitro (Badie et al, 2002). At the same time, Graeber with his 
colleagues scanned 97 glioma samples of different WHO grades and found no such simple 
relations of the MHC expression of the cell with tumor grades, rather found downregulation 
of MHC class II in tissue areas where dense glioblastoma cells were infested. According to 
them microglia were functional in astrocytic tumors, though might be subjected to 
suppression with T cell clonal anergy in that glioma microenvironment (Tran et al, 1998). 
The stimulatory effect of the novel glycoprotein T11TS/SLFA-3 on microglial MHC class II 
expression was found. The dose-time dependent efficient MHC expression was found on 
microglia in rodent bearing experimental glioma when treated with T11TS (Begum et al, 
2004). Chaudhuri and her team also identified another important costimulatory molecule 
CD2 on microglia, which could also be regulated by the glycoprotein dose in glioma 
condition (Begum et al, 2004; Chaudhuri & Ghosh, 2006). A separate study by her team 
found simultaneous co-expression of MHC class II and CD2 on microglia in glioma where 
both expressed in low quantity (Sarkar et al, 2004). This observation with others supported 
the view of immunosuppressive milieu offered to microglia in glioma mostly by TGFǃ, IL-
10, PGE2, gangliosides etc (Zou et al, 1999; Graeber et al, 2002), which could also 
simultaneously cripple the infiltrated lymphocytes (Dix et al, 1999). In this regard, the fact 
that microglia was the source of that IL-10 in glioma, had been finally established by 
Wagner and team (Wagner et al, 1999).  
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Fig. 4. This schematic diagram shows the activities of immune components in brain during 
glioma. After activated glioma antigen specific T cells enter into brain parenchyma they 
progressed towards glioma through parenchyma. Simultaneously, during glioma 
pathogenesis resident resting microglia get activated, upregulate their receptors, enhance 
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their local antigen presenting capacity and move towards glioma vicinity where astrocytic 
projections may assist this movement by providing the pavement for integrin-laminin 
interaction. At the glioma site, microglia locally represent antigens, produce cytokines and 
adhesion molecules to dialogue with lymphocytes which help them to mature and attain 
final effector function. At this point, a triangular complex interaction circuit become active 
between infiltrated lymphocytes, microglia and glioma cells when glioma tries to cripple the 
immune attack by applying many of its tricks (as discussed in the text). Overall cytokine, 
chemokine, growth factor and immunosuppressive factor become crucial to determine the 
success of immune defense or glioma. At the next step, cytotoxic T cells exert perforin, 
granzyme, FasL and other cytotoxic means to kill glioma and microglia uses its reactive 
oxygen and nitrogen intermediates to damage the abnormal or neoplastic cells. Target cells, 
intact, damaged or dead debris are scavenged by microglia. If the immune system manages 
to overcome the situation for a certain period they return to homeostasis. But aggressive 
glioma, after the initial arrest, overrules the immune defense by its rapid proliferation rate, 
immune evasion strategies and diverse modes for bypassing the attack. Gaining dominance 
during the triangular interaction phase marks the success of the party in the succeeding 
phases (Adopted from Chaudhuri & Ghosh, 2006, CNSAMC).  
Hemiberger and colleagues studied the myeloid lineage cells in post-operative tissue 
samples in human glioma. Accepting the cellular identity crisis, these workers found 
macrophage/microglia and dendritic cell populations within the tumor tissue. In their 
higher grade glioma samples microglial population though found to express MHC class II, 
lacked co-stimulatory CD80, CD86 and CD40, crucial for T cell functioning. Activation of 
microglia via Toll-like receptors (TLRs) were also insignificant to augment tumoricidal 
activity (Hussain et al, 2006a). Particularly, proinflammatory cytokines including IL-1ǃ, IL-6, 
TNF ǂ could not be sufficiently released to launch substantial innate immune function 
against glioma, however their phagocytic function was not impaired and also exhibited low 
level of non-specific cytotoxicity (Hussain et al, 2006b). In rodent glioma model lack of 
proinflammatory cytokines IFN Ǆ, IL-12 and IL-6, and conversely cumulative dominance of 
IL-4 and IL-10 favoring the suppression of immune response was recently observed (Ghosh 
et al, 2010). Microglial activity stature was also reflected in their morphometry in scanning 
electron microscopy (SEM), where their filapodial extensions, sizes and shapes had shown 
noticeable alterations (Begum et al, 2003). 
4.5 Microglia can destroy glioma cells 
The cytotoxic effector function is an important part of CNS microglia/macrophage 
population which mainly dependents on its phagocytic mode of action. For the purpose 
super oxide anion production is the major function of phagocytic cells, however microglia 
generate sufficient endogenous NO in addition (Beyer et al, 2000). When microglial effector 
function in rat glioma model was studied, it was found that microglia mostly depends on 
NO production than ROS generation for exerting effector activity, whereas peripheral 
macrophages mainly depends on ROS for their normal phagocytic functions (Ghosh et al, 
2007). With tumoricidal actions NO plays certain role in complex signaling network of 
cytokine production, angiogenesis etc in brain microenvironment. Even microglia was 
found to release iNOS/NO from astrocytoma cells in contact. This was by IL-1ǃ production 
of activated microglia and probably via p38 MAPK and NF-κB signaling pathway (Kim et al, 
2006).  
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Expression of Fas ligand on a cell may cause damage to adjoining cells or infiltrated 
activated lymphocytes in the tissue by triggering the death pathway. In glioma, FasL 
expression was thought to be a means of immune escape, whereas, investigations found 
FasL expression also on microglial cells in glioma (Badie et al, 2001). Hence, it could be 
thought that microglia would play role in local immune suppression by limiting the 
lymphocyte populations; or it might express FasL to damage glioma cells, which in turn 
restricted or crippled the lymphocytes infiltrated locally. Microglia prefers to phagocytose 
the damaged cells rather than intact ones (Bohatschek et al, 2001). A study showed that after 
adoptive transfer of alloreactive cytotoxic T cells in rat 9L gliosarcoma infested brain, the 
CTL damaged glioma cells were removed by phagocytic scavenging activities of microglia, 
whereas undamaged ones were spared (Kulprathipanja & Kruse, 2004). In this process of 
either Fas or oxidative stress mediated cell death, externalization of phosphatidylserine was 
found to be crucial in corpse clearance by microglia. Experimental evidences revealed 
increasing PS externalization in correlation with cytotoxic effector functions of microglia 
and infiltrated lymphocytes. Additionally, the investigation showed that microglia 
population was more steady than infiltrated lymphocytes as Bcl-2 aided the cells to maintain 
that steady turnover rate and low apoptosis in brain microenvironment (Kagan et al, 2002 & 
Ghosh et al, 2007). 
5. Conclusion: Future immuno-therapeutics must capitalize this resident and 
infiltrated immunocyte liaison to combat glioma 
Now it can be clearly stated that lymphocytes can enter into the brain parenchyma. During 
their entry, they are checked by the antigen presenting cells for their glioma antigen 
specificity. APCs try to ensure this glioma specific T cell entry by restimulating the 
candidates presenting the glioma antigens mostly in perivascular space and allied blood 
brain interface (Engelherdt, 2010). After entering they migrate to glioma and again interact 
with the local APCs which help them to gain maturation and final effector function. In this 
process peripheral APC in brain and ‘so called’ resident microglia as well as DCs also play 
very important role. The role of local APC in glioma immunity has been detailed by Ghosh 
and Chaudhuri with a new outlook to explain the contradiction of glioma promoting role of 
microglia (Ghosh and Chaudhuri, 2010).These myeloid cell populations have the potential 
to act as chief immunomodulator in brain by surveillance in the tissue environment, guiding 
the leukocytes in CNS and simultaneously exerting effector function to neoplastic cells. The 
damaging activities of the cell are probably their own misfired ‘goodness’ or their potential 
that is misled by glioma cells. Thus, both the lymphocytes and local APC (predominantly 
microglia) are capable of exerting the immune effector function against glioma in spite of the 
immune-compromise in the brain and glioma immune evasion strategies [Figure – 4]. 
Now the success of immunotherapeutic approaches against glioma, largely as adjuvant 
therapeutic strategy, depends on the proper usages of this delicate immune defense against 
this detrimental threat. The battle becomes more interesting and challenging because the 
opponent is extremely clever. So development of immunotherapeutic strategies against 
glioma needs detailed and critical interpretation of the work-plan of immunity in glioma 
and its careful application. Basic findings are increasing the repertoire of information about 
immune activity deep into the brain during glioma which in turn provide us newer tactics 
or facilitate the amendment of old ones for better effects (Dietrich et al, 2010; Vauleon et al, 
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2010). Even some of the approaches interestingly propose microglia as an effective vehicle 
for gene therapy and drug delivery by using its predifferentiated cellular status (Neumann, 
2006). Present immunotherapeutic advancements and limitations will be discussed in other 
chapters of this book and beyond the scope of this article. In this essay, the basic immune 
mechanisms, which are active in glioma, has been detailed. Further development of effective 
therapy needs this fundamental background knowledge for setting up a new 
immunotherapeutic intervention against glioma. 
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